Menovo(SH:603538)2021-04-19 16:00Financial Performance - Net profit attributable to shareholders rose by 15.43% to CNY 50,345,263.70 year-on-year[8] - Operating revenue grew by 18.55% to CNY 338,290,234.90 compared to the same period last year[8] - Basic earnings per share increased by 13.33% to CNY 0.34[8] - Operating profit for Q1 2021 was ¥62,682,715.24, up from ¥54,940,340.74 in Q1 2020, reflecting a growth of 14.3%[27] - Net profit for Q1 2021 amounted to ¥53,845,524.75, representing a 15.5% increase from ¥46,423,494.57 in Q1 2020[27] - The gross profit margin for Q1 2021 was approximately 34.9%, compared to 35.1% in Q1 2020, showing a slight decrease[26] Assets and Liabilities - Total assets increased by 15.72% to CNY 3,643,086,004.71 compared to the end of the previous year[8] - Current assets totaled CNY 1,658,067,521.29, up from CNY 1,199,262,158.26 at the end of 2020, indicating a growth of about 38.3%[19] - Total liabilities reached CNY 1,700,820,071.93, compared to CNY 1,355,296,200.86 at the end of 2020, representing an increase of approximately 25.5%[20] - Long-term borrowings increased to CNY 196,506,970.87 from CNY 108,506,970.87, reflecting an increase of approximately 81%[20] - The company's equity attributable to shareholders rose to CNY 1,727,813,396.50 from CNY 1,582,222,330.35, indicating a growth of about 9.2%[21] Cash Flow - The net cash flow from operating activities decreased by 118.23% to -CNY 18,738,767.96[8] - The net cash flow from operating activities for Q1 2021 was negative at approximately -¥18.74 million, compared to positive cash flow of ¥102.81 million in Q1 2020[33] - Cash inflow from investment activities in Q1 2021 was approximately ¥152.33 million, while cash outflow was approximately ¥667.39 million, resulting in a net cash flow of -¥515.06 million[33] - Cash inflow from financing activities for Q1 2021 was approximately ¥859.84 million, with a net cash flow of ¥564.78 million after outflows[33] Investments and Acquisitions - The company completed the acquisition of 100% equity in Ningbo High-tech Zone Meinuohua Pharmaceutical Innovation Research Institute for CNY 47,104,000[14] - The company issued convertible bonds totaling CNY 520,000,000, with a net amount of CNY 512,697,629.67 after expenses[13] Shareholder Information - The total number of shareholders reached 21,742 by the end of the reporting period[12] Research and Development - Research and development expenses increased to ¥13,210,864.94 in Q1 2021, up 62.5% from ¥8,146,385.57 in Q1 2020[26] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[27]